+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany



Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany



Bmj Open 8(6): E021082



The Non Interventional Evaluation with Golumimab (GO-NICE) study aimed to document patient and treatment characteristics as well as clinical effectiveness and safety in adult patients newly treated with the tumour necrosis factor inhibitor golimumab (GLM). Prospective non-interventional study with 24-month observation per patient. 158 office-based and clinical-based physicians in Germany. GLM administered in the 50 mg dose subcutaneously in monthly intervals under real-life conditions. Of the 1613 included patients, 1458 patients were eligible for final analysis: 474 patients with rheumatoid arthritis (RA, 54.9±13.4 years, 72.8% women, 64.7% biologic-naïve), 501 with psoriatic arthritis (PsA, 50.5±12.1 years, 54.1% women, 56.5% biologic-naïve) and 483 with ankylosing spondylitis (AS, 43.6±12.3 years, 66.5% men, 61.0% biologic-naïve). 664 patients completed follow-up (2-year retention rate 45.5%). Disease Activity Score 28-joint count erythrocyte sedimentation rate (DAS28-ESR) decreased from 5.0 to 2.9 after 24 months (p<0.0001) in patients with RA, and Bath Ankylosing Spondylitis Disease Index score decreased from 5.1 to 2.4 (p<0.0001) in patients with AS. Response rate calculated in patients with PsA by modified Psoriatic Arthritis Response Criteria was 67.9% after 24 months. Most adverse events were of mild or moderate nature, and no new safety signals were detected. According to the physicians' clinical assessments, treatment with GLM was successful (no adverse drug reaction and a clear or moderate therapeutic effect in an individual patient) in 55.0%-56.6% of patients with RA, PsA and AS, respectively, at month 3, increasing from 74.5% to 76.1% at month 24. GLM subcutaneously once monthly led to substantial improvements in clinical effectiveness in patients with various inflammatory rheumatic diseases who could be followed up in a real-life setting in Germany. The treatment was well tolerated, and the safety profile of GLM was consistent with that observed in the previous randomised controlled trials. NCT01313858.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059558546

Download citation: RISBibTeXText

PMID: 29903793

DOI: 10.1136/bmjopen-2017-021082


Related references

THU0141A Non-Interventional Clinical Study Evaluating The Use of Golimumab in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PSA), and Ankylosing Spondylitis (AS) in A Real-Life Setting in Germany. Annals of the Rheumatic Diseases 75(Suppl 2): 232.2-232, 2016

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. Rheumatology International 39(1): 131-140, 2019

Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Journal of Rheumatology 43(12): 2120-2130, 2016

AB0456Improvement and maintenance of hemoglobin levels among rheumatoid arthritis, psoriatic arthritis & ankylosing spondylitis patients with anemia of inflammation after treatment with golimumab: 3 yr pooled analysis from golimumab rheumatology clinical program. Annals of the Rheumatic Diseases 71(Suppl 3): 663.12-663, 2013

High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients. Clinical and Experimental Rheumatology 36(2): 254-262, 2018

Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Rheumatology 58(3): 441-446, 2019

The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology 52(10): 1845-1855, 2013

Golimumab Utilization Patterns And Refill Adherence In Patients With Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis. Value in Health 17(3): A49-A50, 2014

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Annals of the Rheumatic Diseases 74(3): 538-546, 2015

THU0513Sustained Improvement in Health Related Quality of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated with Golimumab:5yr Results. Annals of the Rheumatic Diseases 72(Suppl 3): A337.2-A337, 2013

Effectiveness and safety of adalimumab (humiha) therapy after failure of prior TNF-antagonists in patients with rheumatoid arthritis (RA), psoriatic arthritis (PSA), and ankylosing spondylitis (AS). 2007

AB0268Lack of correlation between golimumab exposure and selected safety events following intravenous or subcutaneous administration in an integrated analysis of phase 3 data in rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Annals of the Rheumatic Diseases 72(Suppl 3): A868.1-A868, 2013

AB1163Prevalence of Smoking and Impact on Disease Parameters Among Ankylosing Spondylitis, Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Infliximab or Golimumab. Annals of the Rheumatic Diseases 74(Suppl 2): 1291.3-1292, 2015

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Annals of the Rheumatic Diseases 72(4): 517-524, 2013

SAT0130Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohns disease:. Annals of the Rheumatic Diseases 71(Suppl 3): 514.3-515, 2013